Trial Profile
A phase IIa trial investigating the tolerability and pharmacodynamics of Vacc 4x (0.1 or 0.3 mg/dose) for the treatment of HIV-1 infections.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Mar 2018
Price :
$35
*
At a glance
- Drugs Vacc-4x (Primary) ; Molgramostim
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
- 17 Oct 2013 The reboost study will be presented at the Global Health and Vaccination Research conference.
- 07 Aug 2013 Results from the first re-boost clinical trial of Vacc-4x, up to 7 years after the initial vaccination, have been accepted for publication in Vaccine, according to a Bionor Pharma media release.